전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved402 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyCurated CoreFDAstaleRocheApproved

rituximab (Rituxan)

US label: non-Hodgkin lymphoma, CLL, rheumatoid arthritis, GPA/MPA and pemphigus vulgaris; population-specific indicati… · CD20

#CD20#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1337Status Approved
AntibodyCurated CoreFDAstaleJanssenApproved

daratumumab (Darzalex)

Multiple myeloma · CD38

#CD38#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 454Status Approved
AntibodyCurated CoreFDAstaleJohnson & JohnsonApproved

teclistamab-cqyv (Tecvayli, JNJ-64007957, teclistamab)

Relapsed or refractory multiple myeloma · BCMA × CD3

#BCMACD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 132Status Approved
AntibodyCurated CoreFDAstaleRocheApproved

glofitamab (Columvi, RO7082859, glofitamab-gxbm)

Relapsed or refractory diffuse large B-cell lymphoma · CD20 × CD3

#CD20CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 90Status Approved
CGTCurated CoreFDAstaleKiteApproved

axicabtagene ciloleucel (Yescarta, axi-cel)

LBCL, FL · CD19

#CD19#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 68Status Approved
AntibodyCurated CoreFDAstaleGenmabApproved

epcoritamab (Epkinly, GEN3013, Tepkinly, epcoritamab-bysp)

Relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma · CD20 × CD3

#CD20CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 57Status Approved
CGTCurated CoreFDAstaleNovartisApproved

tisagenlecleucel (Kymriah, tisa-cel)

ALL, DLBCL, FL · CD19

#CD19#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 48Status Approved
AntibodyCurated CoreFDAstaleAmgenApproved

tarlatamab (Imdelltra, AMG 757, tarlatamab-dlle)

Extensive-stage small cell lung cancer after platinum-based chemotherapy · DLL3 × CD3

#DLL3CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+4
Trials 39Status Approved
AntibodyCurated CoreFDAstaleRegeneronApproved

linvoseltamab (Lynozyfic, REGN5458, linvoseltamab-gcpt)

Relapsed or refractory multiple myeloma after ≥4 prior lines including a PI, an IMiD, and an anti-CD38 antibody · BCMA × CD3

#BCMACD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 24Status Approved
ADCLimited DatastaleSeagenvedotin combined with the i…Preclinical

recombinant (Brentuximab vedotin, Brentuximab vedotin (recombinant))

Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma · CD30

#CD30#ADC#Preclinical#Popular#antibody-drug-conjugate+4
Trials 219Status Active
CGTLimited DatastaleAstraZenecaPhase 2

autologous CD19-directed chimeric antigen receptor (CAR, autologous CD19-directed chimeric antigen receptor, autologous CD19-directed chimeric antigen receptor (CAR) T-cells)

Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 154Status Recruiting
ADCLimited DatastaleSeagenvedotin and the anti-HER2 t…Preclinical

Genetical Recombination (Brentuximab Vedotin, Brentuximab Vedotin (Genetical Recombination))

Untreated CD30-Positive Hodgkin's Lymphoma · Peripheral T Cell Lymphoma

#PeripheralTCellLymphoma#ADC#Preclinical#Popular#antibody-drug-conjugate+4
Trials 93Status Active
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 1

Anti-CD19 CAR T-cells (Anti-CD19 CAR T-cells)

B Cell Malignancies · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 92Status Recruiting
CGTLimited DatastaleShanghai Ming Ju Biotechnology …Phase 2

CD19-targeted Chimeric Antigen Receptor (CAR, CD19-targeted Chimeric Antigen Receptor, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

Lymphoma, Non-Hodgkin; Diffuse Large B Cell Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 64Status Active
CGTLimited DatastaleTransMolecularPhase 1

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery))

Recurrent Glioblastoma; Recurrent Malignant Glioma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 60Status Recruiting
CGTLimited DatastaleTransMolecularPhase 1

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery))

Recurrent Glioblastoma; Recurrent Malignant Glioma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 60Status Recruiting
CGTLimited DatastaleAbClonPhase 2

Anti-CD19 Chimeric Antigen Receptor T cell (AT101, AT101(Anti-CD19 Chimeric Antigen Receptor T cell))

B-cell Non Hodgkin Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 59Status Recruiting
CGTAAVLimited DatastaleBayerPhase 1

AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV, AAVrh.10hFXN, serotype rh.10 adeno-associated virus, AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN)

Friedreich Ataxia; Cardiomyopathies · Friedreich Ataxia

#FriedreichAtaxia#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 58Status Recruiting
AntibodyLimited DatastaleSeagen Inc.Phase 2

anti-CD30 mAb (SGN-30, SGN-30 (anti-CD30 mAb))

Anaplastic Large-Cell Lymphoma · CD30

#CD30#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 58Status Active
AntibodyLimited DatastaleUCB PharmaPhase 3

CDP870 (Certolizumab Pegol, Certolizumab Pegol (CDP870))

Crohn's Disease · Crohn's Disease

#CrohnsDisease#Antibody#Phase3#Popular#monoclonal-antibody+1
Trials 57Status Active

1 / 21 pages

← PreviousNext →